# OnCo record alemtuzumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/alemtuzumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "alemtuzumab" ;
  schema:name "Alemtuzumab"@en ;
  schema:alternateName "MabCampath"@en, "Lemtrada (multiple sclerosis formulation)"@en, "Campath" ;
  schema:description "Alemtuzumab (Campath) is an antibody that wipes out lymphocytes carrying the CD52 marker. It is approved for chronic lymphocytic leukaemia and is supplied in the US through a restricted distribution programme."@en ;
  schema:url <https://onco.cc/drugs/alemtuzumab/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Alemtuzumab> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=alemtuzumab>, <https://www.cancer.gov/about-cancer/treatment/drugs/alemtuzumab> ;
  onco:status "approved" ;
  onco:tag "nci-list" ;
  onco:modality "Monoclonal antibody (anti-CD52)" ;
  onco:approval "US 2001: B-cell chronic lymphocytic leukaemia (single agent)", "EU 2001: B-CLL after fludarabine (MabCampath; authorisation withdrawn 2012)" ;
  onco:acceleratedApproval "US 2001-05-07: B-cell CLL treated with alkylating agents and failed fludarabine therapy" ;
  onco:acceleratedApprovalConfirmed "US 2007-09-19: B-cell CLL treated with alkylating agents and failed fludarabine therapy" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/cd52/> ;
  onco:companies <https://onco.cc/companies/sanofi/> ;
  onco:trials <https://onco.cc/trials/nct05607420/> .